top of page
Search
kelly1839

LIFT-AD is a Phase 2 Study for the Treatment of Alzheimer's disease

Updated: May 4, 2021

Repairing Brain Cells and Rebuilding Brain Networks


The LIFT-AD trial is evaluating if a new investigational drug (ATH-1017) is safe and effective in improving symptoms of mild to moderate Alzheimer’s disease. ATH-1017 is designed to boost a repair and regenerative pathway for brain cells, promoting brain health and function. ATH-1017 represents a new approach to treat Alzheimer’s disease, potentially targeting the root cause of memory decline by repairing brain cells and rebuilding brain networks.


If you or someone you know has been diagnosed with mild to moderate Alzheimer's disease, consider participation.


LIFT-AD is a research study evaluating an investigational oral medication. ATH-1017 is designed to boost and repair a regenerative pathway for brain cells, promoting brain health and function. To see if you may pre-qualify for the study, call Insight Clinical Trials at (216) 526-1843 or fill out this form.

You may qualify to participate if you or someone you know are:*

  • Have been diagnosed with Alzheimer’s disease

  • Have a reliable support person or caregiver who is willing to participate in study visits, report on daily activities and oversee or help you with taking ATH-1017

*The study doctor will discuss additional requirements.


During the screening visit, you will:

  • Meet with the study doctor and staff

  • Review additional information

  • Have an initial evaluation and undergo tests

  • Complete study questionnaires



If you qualify and decide to participate:

  • A study doctor will monitor your symptoms during the study

  • All study-related medication and medical care will be provided at no cost

  • Eligible participants may receive reasonable compensation for their time and travel.

Please talk to your doctor if you are interested in participating in this study. The safety and efficacy of this investigational drug for the treatment of mild to moderate Alzheimer's has not been previously established.


To learn more about the LIFT-AD study and see if you may qualify, please call us at (216) 526-1843, email info@insightclinicaltrials.com or fill out this online contact form.


Click here to download a patient one-sheet. Free marketing materials are available by calling 216-526-1843.


58 views0 comments

Recent Posts

See All

Comments


bottom of page